Protagonist Therapeutics, Inc.

129 articles with Protagonist Therapeutics, Inc.

• Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 , at 2:00 p.m EST. A live and archived webcast of the event will be available in the Investors section o

• Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)

  12/16/2020

  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide.

• Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/15/2020

  Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its common stock

• Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

  12/11/2020

  Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of $21.00 per share.

• Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories

  12/7/2020

  Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting

• Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

  12/6/2020

  PTG-300 controlled hematocrit and reversed iron deficiency in patients receiving therapeutic phlebotomy, cytoreductive therapy or interferon

• Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera

  12/2/2020

  Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PTG-300 in the treatment of polycythemia vera, a rare disease characterized by the excessive production of red blood cells. PTG-300 is an injectable synthetic peptide mimetic of the nat

• Protagonist Therapeutics Reports Granting of Inducement Award - Dec 01, 2020

  12/1/2020

  Protagonist Therapeutics, Inc. reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the Company's recently hired Vice President, Regulatory Affairs, in accordance with the terms of Dr. Landolfi's employment offer letter.

• Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020

  11/30/2020

   Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020 . The call will include the Protagonist management team and Andrew Kuykendall , M.D., an investigator in the PTG-300

• Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference

  11/25/2020

   Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020 . The presentation will be available for registered

• Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference

  11/11/2020

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020 Time: 5:35 p.m. GMT ( 12:35 p.m. EST

• Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

  11/4/2020

  -- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera -- -- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --

• Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting

  11/4/2020

   Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, taking place in a virtual format December 5-8, 2020 . The abstract data includes results as of early August 2020 from the ongoing Phase 2 study of PTG

• Protagonist Therapeutics Reports Granting of Inducement Award - Oct 30, 2020

  10/30/2020

  Protagonist Therapeutics, Inc. reported that on October 31, 2020, it issued an inducement award to Nora Boyer, the Company's recently hired Vice President, Medical Affairs, in accordance with the terms of Ms. Boyer's employment offer letter.

• Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen

  10/29/2020

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been selected for advancement into clinical development. The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are be

• Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera

  10/21/2020

  PTG-300 was previously granted orphan drug designation by the U.S. Food and Drug Administration

• Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020

  9/17/2020

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.

• Protagonist Therapeutics Reports Granting of Inducement Award - Sep 15, 2020

  9/15/2020

  Protagonist Therapeutics, Inc. reported that on September 15, 2020, it issued an inducement award to Matthew Gosling, the Company's recently hired Executive Vice President and General Counsel, in accordance with the terms of Mr. Gosling's employment offer letter.

• Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference.

• Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar

  9/2/2020

  Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced it will host a "PTG-300 Opportunity Update" webinar on Friday, Sept. 11, 2020 , from 12 p.m. to 1:30 p.m. EDT . The event will feature presentations on clinical needs in polycythemia vera and market research on the potential opportunity for PTG-300. Members o